{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:22:19Z","timestamp":1791206539025,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The JAK2V617F mutation is present in the majority of patients with polycythemia vera and one-half of those with essential thrombocythemia and primary myelofibrosis. JAK2V617F is a gain-of-function mutation resulting in constitutive JAK2 signaling involved in the pathogenesis of these diseases. JAK2V617F has been shown to promote S-phase entry. Here, we demonstrate that the CDC25A phosphatase, a key regulator of the G1\/S cell-cycle transition, is constitutively overexpressed in JAK2V617F-positive cell lines, JAK2-mutated patient CD36+ progenitors, and in vitro\u2013differentiated proerythroblasts. Accordingly, CDC25A is overexpressed in BM and spleen of Jak2V617F knock-in mice compared with wild-type littermates. By using murine FDC-P1\u2013EPOR and human HEL and SET-2 cell lines, we found that JAK2V617F-induced CDC25A up-regulation was caused neither by increased CDC25A transcription or stability nor by the involvement of its upstream regulators Akt and MAPK. Instead, our results suggest that CDC25A is regulated at the translational level through STAT5 and the translational initiation factor eIF2\u03b1. CDC25A inhibition reduces the clonogenic and proliferative potential of JAK2V617F-expressing cell lines and erythroid progenitors while moderately affecting normal erythroid differentiation. These results suggest that CDC25A deregulation may be involved in hematopoietic cells expansion in JAK2V617F patients, making this protein an attracting potential therapeutic target.<\/jats:p>","DOI":"10.1182\/blood-2011-01-327742","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T08:48:04Z","timestamp":1320742084000},"page":"1190-1199","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["The cell cycle regulator CDC25A is a target for JAK2V617F oncogene"],"prefix":"10.1182","volume":"119","author":[{"given":"Emilie-Fleur","family":"Gautier","sequence":"first","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Picard","sequence":"additional","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"},{"name":"Service d'H\u00e9matologie\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"},{"name":"Service d'Anatomie et Cytologie Pathologiques\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Marty","sequence":"additional","affiliation":[{"name":"Inserm U1009, Universit\u00e9 Paris XI, Institut Gustave Roussy, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Villeval","sequence":"additional","affiliation":[{"name":"Inserm U1009, Universit\u00e9 Paris XI, Institut Gustave Roussy, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Demur","sequence":"additional","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"},{"name":"Laboratoire d'H\u00e9matologie\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Delhommeau","sequence":"additional","affiliation":[{"name":"Inserm U1009, Universit\u00e9 Paris XI, Institut Gustave Roussy, Villejuif, France;"},{"name":"Assistance Publique des H\u00f4pitaux de Paris (AP-HP), Laboratoire d'H\u00e9matologie, H\u00f4pital Saint-Antoine, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Giraudier","sequence":"additional","affiliation":[{"name":"Inserm U1009, Universit\u00e9 Paris XI, Institut Gustave Roussy, Villejuif, France;"},{"name":"AP-HP, Laboratoire d'H\u00e9matologie, Universit\u00e9 Paris-Est Cr\u00e9teil, H\u00f4pital Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bonnevialle","sequence":"additional","affiliation":[{"name":"Service d'Orthop\u00e9die\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Ducommun","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France;"},{"name":"Centre Pierre Potier ITAV-UMS3039 CRT-RIV, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"},{"name":"Service d'H\u00e9matologie\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"},{"name":"Service d'H\u00e9matologie\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Manenti","sequence":"additional","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Mansat-De Mas","sequence":"additional","affiliation":[{"name":"Inserm, Unit\u00e9 Mixte de Recherche 1037\u2013Cancer Research Center of Toulouse, Universit\u00e9 de Toulouse, Centre Hospitalier Universitaire Purpan, Toulouse, France;"},{"name":"Laboratoire d'H\u00e9matologie\u2013Centre Hospitalier Universitaire Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7037","key":"2019111808160659900_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"9464","key":"2019111808160659900_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"2019111808160659900_B3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111808160659900_B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111808160659900_B5","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111808160659900_B6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knockin mice.","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111808160659900_B7","doi-asserted-by":"crossref","first-page":"18177","DOI":"10.1074\/jbc.M600064200","article-title":"Activated Jak2 with the V617F point mutation promotes G1\/S phase transition.","volume":"281","author":"Walz","year":"2006","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111808160659900_B8","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.leu.2404361","article-title":"Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators.","volume":"20","author":"Leli\u00e8vre","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"2019111808160659900_B9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrc2169","article-title":"CDC25 phosphatases in cancer cells: key players? Good targets?","volume":"7","author":"Boutros","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2019111808160659900_B10","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1128\/MCB.19.7.4695","article-title":"Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression.","volume":"19","author":"Chen","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"10","key":"2019111808160659900_B11","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/MCB.20.10.3497-3509.2000","article-title":"Involvement of Myc activity in a G(1)\/S-promoting mechanism parallel to the pRb\/E2F pathway.","volume":"20","author":"Santoni-Rugiu","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"16","key":"2019111808160659900_B12","doi-asserted-by":"crossref","first-page":"15673","DOI":"10.1074\/jbc.M413203200","article-title":"The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter.","volume":"280","author":"Barr \u00e9","year":"2005","journal-title":"J Biol Chem"},{"issue":"11","key":"2019111808160659900_B13","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/sj.onc.1207394","article-title":"Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis.","volume":"23","author":"Busino","year":"2004","journal-title":"Oncogene"},{"issue":"5","key":"2019111808160659900_B14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1083\/jcb.200409099","article-title":"Cytokine-driven cell cycling is mediated through Cdc25A.","volume":"169","author":"Khaled","year":"2005","journal-title":"J Cell Biol"},{"issue":"1","key":"2019111808160659900_B15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccr.2007.12.002","article-title":"GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.","volume":"13","author":"Kang","year":"2008","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111808160659900_B16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/ncb2041","article-title":"Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A.","volume":"12","author":"Pereg","year":"2010","journal-title":"Nat Cell Biol"},{"issue":"3","key":"2019111808160659900_B17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/0008-5472.CAN-06-3927","article-title":"Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.","volume":"67","author":"Ray","year":"2007","journal-title":"Cancer Res"},{"issue":"14","key":"2019111808160659900_B18","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1158\/0008-5472.CAN-06-4815","article-title":"Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice.","volume":"67","author":"Ray","year":"2007","journal-title":"Cancer Res"},{"issue":"14","key":"2019111808160659900_B19","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1158\/0008-5472.CAN-05-2552","article-title":"Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia.","volume":"66","author":"Fernandez-Vidal","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"2019111808160659900_B20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4161\/cc.8.9.8302","article-title":"Upregulation of the CDC25A phosphatase down-stream of the NPM\/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.","volume":"8","author":"Fernandez-Vidal","year":"2009","journal-title":"Cell Cycle"},{"issue":"6","key":"2019111808160659900_B21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/ijc.24080","article-title":"IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells.","volume":"124","author":"Brezak","year":"2009","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111808160659900_B22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/13543771003623232","article-title":"Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.","volume":"20","author":"Lavecchia","year":"2010","journal-title":"Expert Opin Ther Pat"},{"issue":"10","key":"2019111808160659900_B23","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111808160659900_B24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","article-title":"New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1\/S-phase transition.","volume":"22","author":"Chalign\u00e9","year":"2008","journal-title":"Leukemia"},{"issue":"50","key":"2019111808160659900_B25","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1038\/sj.onc.1206976","article-title":"Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.","volume":"22","author":"L\u00f6ffler","year":"2003","journal-title":"Oncogene"},{"issue":"10","key":"2019111808160659900_B26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm1488","article-title":"Molecular mechanisms of translational control.","volume":"5","author":"Gebauer","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"2019111808160659900_B27","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1158\/0008-5472.CAN-08-0625","article-title":"Multimodal control of Cdc25A by nitrosative stress.","volume":"68","author":"Tomko","year":"2008","journal-title":"Cancer Res"},{"issue":"Pt 1","key":"2019111808160659900_B28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/BST0340007","article-title":"Coping with stress: eIF2 kinases and translational control.","volume":"34","author":"Wek","year":"2006","journal-title":"Biochem Soc Trans"},{"issue":"22","key":"2019111808160659900_B29","doi-asserted-by":"crossref","first-page":"17098","DOI":"10.1074\/jbc.M110.109439","article-title":"eIF2alpha phosphorylation tips the balance to apoptosis during osmotic stress.","volume":"285","author":"Bevilacqua","year":"2010","journal-title":"J Biol Chem"},{"issue":"9","key":"2019111808160659900_B30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM199802263380902","article-title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.","volume":"338","author":"Silva","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111808160659900_B31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","article-title":"Bcl-2\u2013independent Bcr-Abl\u2013mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.","volume":"16","author":"Amarante-Mendes","year":"1998","journal-title":"Oncogene"},{"issue":"5","key":"2019111808160659900_B32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells.","volume":"108","author":"Gar\u00e7on","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111808160659900_B33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bbrc.2009.04.015","article-title":"p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation.","volume":"383","author":"Furuhata","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2019111808160659900_B34","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111808160659900_B35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1517\/13543771003639436","article-title":"Recent developments on JAK2 inhibitors: a patent review.","volume":"20","author":"Kiss","year":"2010","journal-title":"Expert Opin Ther Pat"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/5\/1190\/1356802\/zh800512001190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/5\/1190\/1356802\/zh800512001190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:36:24Z","timestamp":1574084184000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/5\/1190\/29824\/The-cell-cycle-regulator-CDC25A-is-a-target-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,2]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,2,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-327742","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,2]]}}}